These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 18475181)

  • 1. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
    Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J; First MR;
    Transplantation; 2008 May; 85(9):1261-9. PubMed ID: 18475181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
    Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
    Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
    Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M; Morales JM; Marcen R; Campistol JM; Oppenheimer F; Serón D; Gil-Vernet S; Capdevila L; Andrés A; Lampreave I; Del Castillo D; Cabello M; Burgos D; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
    Transplant Proc; 2007 Sep; 39(7):2167-9. PubMed ID: 17889126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
    Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
    Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
    Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
    J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
    Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
    Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy.
    Ji SM; Li LS; Sha GZ; Chen JS; Liu ZH
    Transplant Proc; 2007 Jun; 39(5):1402-5. PubMed ID: 17580148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
    Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
    Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.
    Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.